查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1599297

病毒載體市場：按類型、疾病、應用和最終用戶分類 - 2025-2030 年全球預測

Viral Vectors Market by Type (Adeno-associated Viral Vectors, Adenoviral Vectors, Retroviral Vectors), Disease (Cancers, Genetic Disorders, Infectious Diseases), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

病毒載體市場2023年估值為16.6億美元，預計2024年將達18.8億美元，複合年成長率為14.09%，預計2030年將達到41.8億美元。

作為 360iResearch 的市場研究分析師，對病毒載體市場的調查揭示了其作為基因治療、疫苗開發和分子生物學中用於將遺傳物質傳遞到細胞中的重要工具的範圍。對病毒載體的需求源於它們在重要的醫療保健解決方案中的應用，包括遺傳疾病、感染疾病和癌症的治療，因為它們能夠促進有效的基因轉移。最終用途範圍主要包括製藥和生物技術公司、研究機構和專注於推進基因研究和開發新療法的臨床實驗室。主要成長動力包括研發投資的增加、基因治療技術的進步以及需要創新治療的慢性病盛行率上升。此外，載體設計和遞送系統的技術進步為提高安全性和效率提供了潛在的機會，這對於充分發揮基因治療的潛力至關重要。然而，市場成長面臨製造成本高、法律規範複雜以及患者潛在免疫抗原性等挑戰。創新應著重於改進載體傳遞機制、最大限度地減少副作用和開發可擴展的製造流程。此外，鼓勵與學術和臨床研究機構合作，以促進開發具有成本效益和有針對性的載體解決方案。此外，對非病毒傳遞方法的進一步探索可能會彌補當前病毒載體帶來的局限性，並為更安全、更有效的治療鋪平道路。市場競爭激烈，不斷的創新和合作夥伴關係塑造著格局，凸顯了對策略性研發投資和敏捷的打入市場策略的需求。為了利用快速成長的商機，相關人員正在專注於將先進的分析和機器學習工具整合到研究工作中，以提高治療開發的精確度並增強病毒載體應用的擴充性和採用率。

主要市場統計
基準年[2023] 16.6億美元
預測年份 [2024] 18.8億美元
預測年份 [2030] 41.8億美元
複合年成長率（%） 14.09%

市場動態：揭示快速發展的病毒載體市場的關鍵市場洞察

供需的動態交互作用正在改變病毒載體市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 增加針對各種感染疾病和病毒的疫苗產量
    • 目標疾病和疾病的盛行率增加
    • 細胞和基因治療的政府舉措
  • 市場限制因素
    • 基因和細胞治療成本上升
  • 市場機會
    • 罕見疾病治療的持續研究和開發
    • 大型合約開發/製造公司的投資
  • 市場挑戰
    • 插入突變和免疫反應的風險

波特五力：駕馭病毒載體市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解病毒載體市場的外部影響

外部宏觀環境因素在塑造病毒載體市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解病毒載體市場的競爭狀況

對病毒載體市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣病毒載體市場供應商績效評估

FPNV定位矩陣是評估病毒載體市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了病毒載體市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對病毒載體市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加針對各種感染疾病和病毒的疫苗產量
      • 目標疾病和疾病的盛行率增加
      • 政府關於細胞和基因治療的舉措
    • 抑制因素
      • 基因/細胞治療費用高
    • 機會
      • 罕見疾病治療的持續研究和開發
      • 大型開發和受託製造組織的投資
    • 任務
      • 插入突變和免疫反應的風險
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章病毒載體市場：依類型

  • 腺結合病毒載體
  • 腺病毒載體
  • 逆轉錄病毒載體

第7章病毒載體市場：依疾病分類

  • 癌症
  • 遺傳疾病
  • 感染疾病

第8章病毒載體市場：依應用分類

  • 基因治療
  • 疫苗學

第9章病毒載體市場：依最終用戶分類

  • 製藥和生物製藥公司
  • 調查機構

第10章美洲病毒載體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區病毒載體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的病毒載體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • ABL Inc.
  • Batavia Biosciences BV
  • Bio-Rad Laboratories, Inc.
  • BioNTech IMFS GmbH
  • Biovian Oy
  • Cevec Pharmaceuticals GmbH
  • Creative Biogene
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • GeneOne Life Science, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-957C47F9405B

The Viral Vectors Market was valued at USD 1.66 billion in 2023, expected to reach USD 1.88 billion in 2024, and is projected to grow at a CAGR of 14.09%, to USD 4.18 billion by 2030.

As a Market Research Analyst at 360iResearch, the exploration of the viral vectors market uncovers its scope as integral tools used in gene therapy, vaccine development, and molecular biology to deliver genetic material into cells. The necessity of viral vectors stems from their application in critical healthcare solutions, including the treatment of genetic disorders, infectious diseases, and cancers, owing to their ability to facilitate efficient gene transfer. End-use scope primarily encompasses pharmaceutical and biotechnology companies, research institutions, and clinical laboratories focused on advancing genetic research and developing novel therapeutics. Key growth drivers include increasing research and development investments, advancements in gene therapy techniques, and rising prevalence of chronic diseases demanding innovative treatments. Furthermore, technological advancements in vector design and delivery systems open potential opportunities for enhancement in safety and efficiency, vital for harnessing the full potential of gene therapies. Nevertheless, market growth faces challenges such as high production costs, complex regulatory frameworks, and potential immunogenicity in patients. Innovations should focus on improving vector delivery mechanisms, minimizing adverse effects, and developing scalable manufacturing processes. Moreover, collaborations with academic and clinical research institutions are recommended to drive the development of cost-effective and targeted vector solutions. Further exploration into non-viral delivery methods might also bridge the limitations posed by current viral vectors, paving the way for safer and more efficient therapies. The nature of the market is intensely competitive, with continuous innovations and partnerships shaping its landscape, thus emphasizing the need for strategic R&D investments and agile market entry strategies. To capitalize on the burgeoning opportunities, stakeholders should focus on integrating advanced analytics and machine learning tools in their research efforts, enabling precision in therapeutic development and enhancing the scalability and adoption of viral vector applications.

KEY MARKET STATISTICS
Base Year [2023] USD 1.66 billion
Estimated Year [2024] USD 1.88 billion
Forecast Year [2030] USD 4.18 billion
CAGR (%) 14.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Vectors Market

The Viral Vectors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing vaccine production for various infections and viruses
    • Growing prevalence of target ailments and diseases
    • Government initiatives for cell and gene therapy treatments
  • Market Restraints
    • High cost of gene & cell therapy treatments
  • Market Opportunities
    • Ongoing research and development in rare disease treatments
    • Investments by large contract development and manufacturing organizations
  • Market Challenges
    • Risk of insertional mutagenesis and immune response

Porter's Five Forces: A Strategic Tool for Navigating the Viral Vectors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Vectors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Vectors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Vectors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Vectors Market

A detailed market share analysis in the Viral Vectors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Vectors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Vectors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Viral Vectors Market

A strategic analysis of the Viral Vectors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Viral Vectors Market, highlighting leading vendors and their innovative profiles. These include ABL Inc., Batavia Biosciences B.V., Bio-Rad Laboratories, Inc., BioNTech IMFS GmbH, Biovian Oy, Cevec Pharmaceuticals GmbH, Creative Biogene, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., GeneOne Life Science, Inc., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Sirion-Biotech GmbH, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Viral Vectors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Adeno-associated Viral Vectors, Adenoviral Vectors, and Retroviral Vectors.
  • Based on Disease, market is studied across Cancers, Genetic Disorders, and Infectious Diseases.
  • Based on Application, market is studied across Gene Therapy and Vaccinology.
  • Based on End User, market is studied across Pharmaceutical & Biopharmaceutical Companies and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing vaccine production for various infections and viruses
      • 5.1.1.2. Growing prevalence of target ailments and diseases
      • 5.1.1.3. Government initiatives for cell and gene therapy treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of gene & cell therapy treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development in rare disease treatments
      • 5.1.3.2. Investments by large contract development and manufacturing organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of insertional mutagenesis and immune response
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Viral Vectors Market, by Type

  • 6.1. Introduction
  • 6.2. Adeno-associated Viral Vectors
  • 6.3. Adenoviral Vectors
  • 6.4. Retroviral Vectors

7. Viral Vectors Market, by Disease

  • 7.1. Introduction
  • 7.2. Cancers
  • 7.3. Genetic Disorders
  • 7.4. Infectious Diseases

8. Viral Vectors Market, by Application

  • 8.1. Introduction
  • 8.2. Gene Therapy
  • 8.3. Vaccinology

9. Viral Vectors Market, by End User

  • 9.1. Introduction
  • 9.2. Pharmaceutical & Biopharmaceutical Companies
  • 9.3. Research Institutes

10. Americas Viral Vectors Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Viral Vectors Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Viral Vectors Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ABL Inc.
  • 2. Batavia Biosciences B.V.
  • 3. Bio-Rad Laboratories, Inc.
  • 4. BioNTech IMFS GmbH
  • 5. Biovian Oy
  • 6. Cevec Pharmaceuticals GmbH
  • 7. Creative Biogene
  • 8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 9. GeneOne Life Science, Inc.
  • 10. Lonza Group Ltd.
  • 11. Merck KGaA
  • 12. Miltenyi Biotec B.V. & Co. KG
  • 13. Sirion-Biotech GmbH
  • 14. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VIRAL VECTORS MARKET RESEARCH PROCESS
  • FIGURE 2. VIRAL VECTORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VIRAL VECTORS MARKET DYNAMICS
  • TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2023